#161758

IVRO1 Cell Line

Cat. #161758

IVRO1 Cell Line

Cat. #: 161758

Availability: 8-10 weeks

Organism: Human

Tissue: Ovary

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Michelle Lockley

Institute: Queen Mary University of London, UK.

Primary Citation: J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: IVRO1 Cell Line
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Parental cell: OVCAR4-Luc cell lines
  • Organism: Human
  • Gender: Female
  • Tissue: Ovary
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Platinum-resistant HGSC in vivo cell line
  • Crispr: No
  • Description: Platinum-resistant HGSC cancer cells with a growth advantage in the presence of therapy that expand to create drug-resistant tumours.
  • Production details: Mice with OVCAR4 intraperitoneal xenografts initially responded to carboplatin but tumours eventually regrew indicating the in vivo development of carboplatin-resistance. Murine tumours were harvested at necropsy and dissociated to create IVR01.

Handling

  • Growth medium: DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained.
  • Temperature: 37° C
  • Initial handling information: Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained
  • Cultured in antibiotics: Streptomycin and Penicillin
  • Mycoplasma free: Yes
  • Str profiling: 16 locus STR verification (DNA Diagnostics Centre, London, UK: June 2015?February 2016 and European Collection of Authenticated Cell Lines August 2019)

References

  • J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.